Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Hedge Funds

13G Filing: Biotechnology Value Fund L P and Arqule Inc (ARQL)

Published on October 16, 2017 at 1:55 pm by Insider Monkey Staff in Hedge Funds

Arqule Inc (NASDAQ:ARQL): Mark Lampert’s Biotechnology Value Fund LP filed an amended 13D.

You can check out Biotechnology Value Fund LP’s latest holdings and filings here.

Please follow Biotechnology Value Fund LP (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Biotechnology Value Fund LP or update its stock holdings.

Follow Mark Lampert's Biotechnology Value Fund / BVF Inc

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Biotechnology Value Fund 0 0 8,820,763 8,820,763 10.0%
Biotechnology Value Fund II 0 0 5,124,370 5,124,370 5.8%
Biotechnology Value Trading Fund OS 0 0 1,378,980 1,378,980 1.6%
BVF Partners OS Ltd 0 0 1,378,980 1,378,980 1.6%
BVF Partners 0 0 17,553,114 17,553,114 19.9%
BVF Inc 0 0 17,553,114 17,553,114 19.9%
Mark N. Lampert 0 0 17,553,114 17,553,114 19.9%

Page 1 of 14 – SEC Filing

 UNITED STATES

SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b), (c),
AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No.
5)1

ArQule, Inc.

 (Name of Issuer)

Common Stock, par value $0.01 per share

 (Title of Class of Securities)

04269E107

 (CUSIP Number)

October 11, 2017

 (Date of Event Which Requires Filing of this
Statement)

Check the appropriate box
to designate the rule pursuant to which this Schedule is filed:

 ☐  Rule 13d-1(b)
 ☒  Rule 13d-1(c)
 ☐  Rule 13d-1(d)

1
The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to
the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided
in a prior cover page.

The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).

Follow Arqule Inc (NASDAQ:ARQL)

Page 2 of 14 – SEC Filing

1 NAME OF REPORTING PERSON
Biotechnology Value Fund, L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 8,820,763 (1)
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
8,820,763 (1)
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
8,820,763 (1)
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		     ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
10.0% (1)
12 TYPE OF REPORTING PERSON
PN
(1)

Includes
1,115,932 shares of Common Stock currently issuable upon the exercise of certain warrants. As of October 16, 2017, the warrant
exercise limitation described in the next sentence limits the aggregate exercise of warrants by the Reporting Persons to 1,115,932
out of the 2,439,932 shares of Common Stock underlying the warrants owned by the Reporting Persons in the aggregate. The warrants
may not be exercised if, after such exercise, the Reporting Persons would beneficially own in the aggregate, as determined in
accordance with Section 13(d) of the Securities Exchange Act of 1934, more than 19.9% of the number of shares of Common Stock
then issued and outstanding. In providing beneficial ownership described herein, the Reporting Persons have assumed 1,115,932
of the 1,201,053 warrants owned by BVF would be exercised. BVF2 holds warrants to purchase 823,231 additional shares which are
excluded herein as a result of the 19.9% limitation. BVTOS holds warrants to purchase 199,687 additional shares which are excluded
herein as a result of the 19.9% limitation. The Reporting Persons through certain managed accounts holds warrants to purchase
215,961 additional shares which are excluded herein as a result of the 19.9% limitation. See Item 4(a) for a full description
of the Reporting Person’s beneficial ownership.
2

Follow Arqule Inc (NASDAQ:ARQL)

Page 3 of 14 – SEC Filing

1 NAME OF REPORTING PERSON
Biotechnology Value Fund II, L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 5,124,370 (1)
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
5,124,370 (1)
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,124,370 (1)
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		     ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
5.8% (1)
12 TYPE OF REPORTING PERSON
PN
(1) Excludes 823,231 shares of Common Stock not issuable upon the exercise of certain warrants due to the warrant
exercise limitation. As of October 16, 2017, the warrant exercise limitation described in the next sentence limits the aggregate
exercise of warrants by the Reporting Persons to 1,115,932 out of the 2,439,932 shares of Common Stock underlying the warrants
owned by the Reporting Persons in the aggregate. The warrants may not be exercised if, after such exercise, the Reporting Persons
would beneficially own in the aggregate, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934,
more than 19.9% of the number of shares of Common Stock then issued and outstanding. In providing beneficial ownership described
herein, the Reporting Persons have assumed 1,115,932 of the 1,201,053 warrants owned by BVF would be exercised. BVF2 holds warrants
to purchase 823,231 additional shares which are excluded herein as a result of the 19.9% limitation. BVTOS holds warrants to purchase
199,687 additional shares which are excluded herein as a result of the 19.9% limitation. The Reporting Persons through certain
managed accounts holds warrants to purchase 215,961 additional shares which are excluded herein as a result of the 19.9% limitation.
See Item 4(a) for a full description of the Reporting Person’s beneficial ownership.
3

Follow Arqule Inc (NASDAQ:ARQL)

Page 4 of 14 – SEC Filing

1 NAME OF REPORTING PERSON
Biotechnology Value Trading Fund OS LP
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 1,378,980 (1)
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
1,378,980 (1)
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,378,980 (1)
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		     ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
1.6% (1)
12 TYPE OF REPORTING PERSON
PN
(1)

Excludes
199,687 shares of Common Stock not issuable upon the exercise of certain warrants due to the warrant exercise limitation. As of
October 16, 2017, the warrant exercise limitation described in the next sentence limits the aggregate exercise of warrants by
the Reporting Persons to 1,115,932 out of the 2,439,932 shares of Common Stock underlying the warrants owned by the Reporting
Persons in the aggregate. The warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially
own in the aggregate, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, more than 19.9% of
the number of shares of Common Stock then issued and outstanding. In providing beneficial ownership described herein, the Reporting
Persons have assumed 1,115,932 of the 1,201,053 warrants owned by BVF would be exercised. BVF2 holds warrants to purchase 823,231
additional shares which are excluded herein as a result of the 19.9% limitation. BVTOS holds warrants to purchase 199,687 additional
shares which are excluded herein as a result of the 19.9% limitation. The Reporting Persons through certain managed accounts holds
warrants to purchase 215,961 additional shares which are excluded herein as a result of the 19.9% limitation. See Item 4(a) for
a full description of the Reporting Person’s beneficial ownership.
4

Follow Arqule Inc (NASDAQ:ARQL)

Page 5 of 14 – SEC Filing

1 NAME OF REPORTING PERSON
BVF Partners OS Ltd.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 1,378,980 (1)
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
1,378,980 (1)
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,378,980 (1)
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		     ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
1.6% (1)
12 TYPE OF REPORTING PERSON
CO
(1)

Excludes
199,687 shares of Common Stock not issuable upon the exercise of certain warrants due to the warrant exercise limitation. As of
October 16, 2017, the warrant exercise limitation described in the next sentence limits the aggregate exercise of warrants by
the Reporting Persons to 1,115,932 out of the 2,439,932 shares of Common Stock underlying the warrants owned by the Reporting
Persons in the aggregate. The warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially
own in the aggregate, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, more than 19.9% of
the number of shares of Common Stock then issued and outstanding. In providing beneficial ownership described herein, the Reporting
Persons have assumed 1,115,932 of the 1,201,053 warrants owned by BVF would be exercised. BVF2 holds warrants to purchase 823,231
additional shares which are excluded herein as a result of the 19.9% limitation. BVTOS holds warrants to purchase 199,687 additional
shares which are excluded herein as a result of the 19.9% limitation. The Reporting Persons through certain managed accounts holds
warrants to purchase 215,961 additional shares which are excluded herein as a result of the 19.9% limitation. See Item 4(a) for
a full description of the Reporting Person’s beneficial ownership.
5

Follow Arqule Inc (NASDAQ:ARQL)

Page 6 of 14 – SEC Filing

1 NAME OF REPORTING PERSON
BVF Partners L.P.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 17,553,114 (1)
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
17,553,114 (1)
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
17,553,114 (1)
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		     ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
19.9% (1)
12 TYPE OF REPORTING PERSON
PN, IA
(1)

Includes
1,115,932 shares of Common Stock currently issuable upon the exercise of certain warrants. Excludes 1,324,000 shares of Common
Stock not issuable upon the exercise of certain warrants due to the warrant exercise limitation. As of October 16, 2017, the warrant
exercise limitation described in the next sentence limits the aggregate exercise of warrants by the Reporting Persons to 1,115,932
out of the 2,439,932 shares of Common Stock underlying the warrants owned by the Reporting Persons in the aggregate. The warrants
may not be exercised if, after such exercise, the Reporting Persons would beneficially own in the aggregate, as determined in
accordance with Section 13(d) of the Securities Exchange Act of 1934, more than 19.9% of the number of shares of Common Stock
then issued and outstanding. In providing beneficial ownership described herein, the Reporting Persons have assumed 1,115,932
of the 1,201,053 warrants owned by BVF would be exercised. BVF2 holds warrants to purchase 823,231 additional shares which are
excluded herein as a result of the 19.9% limitation. BVTOS holds warrants to purchase 199,687 additional shares which are excluded
herein as a result of the 19.9% limitation. The Reporting Persons through certain managed accounts holds warrants to purchase
215,961 additional shares which are excluded herein as a result of the 19.9% limitation. See Item 4(a) for a full description
of the Reporting Person’s beneficial ownership.
6

Follow Arqule Inc (NASDAQ:ARQL)

Page 7 of 14 – SEC Filing

1 NAME OF REPORTING PERSON
BVF Inc.
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 17,553,114 (1)
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
17,553,114 (1)
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
17,553,114 (1)
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		     ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
19.9% (1)
12 TYPE OF REPORTING PERSON
CO
(1)

Includes
1,115,932 shares of Common Stock currently issuable upon the exercise of certain warrants. Excludes 1,324,000 shares of Common
Stock not issuable upon the exercise of certain warrants due to the warrant exercise limitation. As of October 16, 2017, the warrant
exercise limitation described in the next sentence limits the aggregate exercise of warrants by the Reporting Persons to 1,115,932
out of the 2,439,932 shares of Common Stock underlying the warrants owned by the Reporting Persons in the aggregate. The warrants
may not be exercised if, after such exercise, the Reporting Persons would beneficially own in the aggregate, as determined in
accordance with Section 13(d) of the Securities Exchange Act of 1934, more than 19.9% of the number of shares of Common Stock
then issued and outstanding. In providing beneficial ownership described herein, the Reporting Persons have assumed 1,115,932
of the 1,201,053 warrants owned by BVF would be exercised. BVF2 holds warrants to purchase 823,231 additional shares which are
excluded herein as a result of the 19.9% limitation. BVTOS holds warrants to purchase 199,687 additional shares which are excluded
herein as a result of the 19.9% limitation. The Reporting Persons through certain managed accounts holds warrants to purchase
215,961 additional shares which are excluded herein as a result of the 19.9% limitation. See Item 4(a) for a full description
of the Reporting Person’s beneficial ownership.
7

Follow Arqule Inc (NASDAQ:ARQL)

Page 8 of 14 – SEC Filing

1 NAME OF REPORTING PERSON
Mark N. Lampert
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ☒
(b) ☐
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
NUMBER OF 5 SOLE VOTING POWER
SHARES
BENEFICIALLY 0 shares
OWNED BY 6 SHARED VOTING POWER
EACH
REPORTING 17,553,114 (1)
PERSON WITH 7 SOLE DISPOSITIVE POWER
0 shares
8 SHARED DISPOSITIVE POWER
17,553,114 (1)
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
17,553,114 (1)
10 CHECK BOX IF THE
AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES		     ☐
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
19.9% (1)
12 TYPE OF REPORTING PERSON
IN
(1)

Includes
1,115,932 shares of Common Stock currently issuable upon the exercise of certain warrants. Excludes 1,324,000 shares of Common
Stock not issuable upon the exercise of certain warrants due to the warrant exercise limitation. As of October 16, 2017, the warrant
exercise limitation described in the next sentence limits the aggregate exercise of warrants by the Reporting Persons to 1,115,932
out of the 2,439,932 shares of Common Stock underlying the warrants owned by the Reporting Persons in the aggregate. The warrants
may not be exercised if, after such exercise, the Reporting Persons would beneficially own in the aggregate, as determined in
accordance with Section 13(d) of the Securities Exchange Act of 1934, more than 19.9% of the number of shares of Common Stock
then issued and outstanding. In providing beneficial ownership described herein, the Reporting Persons have assumed 1,115,932
of the 1,201,053 warrants owned by BVF would be exercised. BVF2 holds warrants to purchase 823,231 additional shares which are
excluded herein as a result of the 19.9% limitation. BVTOS holds warrants to purchase 199,687 additional shares which are excluded
herein as a result of the 19.9% limitation. The Reporting Persons through certain managed accounts holds warrants to purchase
215,961 additional shares which are excluded herein as a result of the 19.9% limitation. See Item 4(a) for a full description
of the Reporting Person’s beneficial ownership.
8

Follow Arqule Inc (NASDAQ:ARQL)

Page 9 of 14 – SEC Filing

Item 1(a). Name of Issuer:

ArQule, Inc., a Delaware corporation (the “Issuer”).

Item 1(b). Address of Issuer’s Principal Executive Offices:

One Wall Street

Burlington, Massachusetts 01803

Item 2(a). Name of Person Filing
Item 2(b). Address of Principal Business Office or, if None, Residence
Item 2(c). Citizenship

Biotechnology Value Fund, L.P. (“BVF”)

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Fund II, L.P. (“BVF2”)

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: Delaware

Biotechnology Value Trading Fund OS
LP (“Trading Fund OS”)

PO Box 309 Ugland House

Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners OS Ltd. (“Partners
OS”)

PO Box 309 Ugland House

Grand Cayman, KY1-1104

Cayman Islands

Citizenship: Cayman Islands

BVF Partners L.P. (“Partners”)

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: Delaware

BVF Inc.

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: Delaware

Mark N. Lampert (“Mr. Lampert”)

1 Sansome Street, 30th Floor

San Francisco, California 94104

Citizenship: United States

Each of the foregoing is referred to
as a “Reporting Person” and collectively as the “Reporting Persons.”

9

Follow Arqule Inc (NASDAQ:ARQL)

Page 10 of 14 – SEC Filing

Item 2(d). Title of Class of Securities:

Common Stock, par value $0.01 per share (the “Common
Stock”)

Item 2(e). CUSIP Number:

04269E107

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person
Filing is a:
/x/ Not applicable.
(a) / / Broker or dealer registered under Section 15 of the Exchange Act.
(b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
(c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d) / / Investment company registered under Section 8 of the Investment Company Act.
(e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
(j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____
Item 4. Ownership
(a) Amount beneficially owned:

On October 11, 2017, the Reporting
Persons participated in a private placement (the “Private Placement”) with the Issuer. Pursuant to the Private Placement,
the Reporting Persons acquired in the aggregate 9,037,054 Shares of Common Stock and warrants (the “Warrants”) exercisable
for an aggregate of 2,439,932 Shares of Common Stock. Pursuant to the Private Placement, the Warrants are subject to an exercise
limitation, and may not be exercised if, after such exercise, the Reporting Persons would beneficially own in the aggregate, as
determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, more than 19.9% of the number of shares of
Common Stock then issued and outstanding. Such Warrants have an initial exercise price of $1.75 per Share, subject to adjustment
pursuant to the terms of the Warrants, and expire on October 11, 2021. As of October 16, 2017, the warrant exercise limitation
described in the prior sentence limits the aggregate exercise of the Warrants by the Reporting Persons to 1,115,932 out of the
2,439,932 shares of Common Stock underlying the Warrants owned by the Reporting Persons in the aggregate. In providing beneficial
ownership described herein, the Reporting Persons have assumed 1,115,932 of the 1,201,053 warrants owned by BVF would be exercised.
BVF2 holds warrants to purchase 823,231 additional shares which are excluded herein as a result of the 19.9% limitation. BVTOS
holds warrants to purchase 199,687 additional shares which are excluded herein as a result of the 19.9% limitation. The Reporting
Persons through certain managed accounts holds warrants to purchase 215,961 additional shares which are excluded herein as a result
of the 19.9% limitation.

10

Follow Arqule Inc (NASDAQ:ARQL)

Page 11 of 14 – SEC Filing

As of October
16, 2017 (i) BVF beneficially owned 8,820,763 shares of Common Stock, including 1,115,932 shares of Common Stock issuable upon
the exercise of certain Warrants, (ii) BVF2 beneficially owned 5,124,370 shares of Common Stock, and (iii) Trading Fund OS beneficially
owned 1,378,980 shares of Common Stock.

Partners OS as the general partner
of Trading Fund OS may be deemed to beneficially own the 1,378,980 shares of Common Stock beneficially owned by Trading Fund OS.

Partners, as the general partner of
BVF, BVF2, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the
17,553,114 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and certain Partners managed
accounts (the “Partners Managed Accounts”), including 2,229,001 shares of Common Stock held in the Partners Managed
Accounts.

BVF Inc., as the general partner of
Partners, may be deemed to beneficially own the 17,553,114 shares of Common Stock beneficially owned by Partners.

Mr. Lampert, as a director and officer
of BVF Inc., may be deemed to beneficially own the 17,553,114 shares of Common Stock beneficially owned by BVF Inc.

The foregoing should not be construed
in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another
Reporting Person. Partners OS disclaims beneficial ownership of the shares of Common Stock beneficially owned by Trading Fund OS.
Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF,
BVF2, Trading Fund OS, and the Partners Managed Accounts, and the filing of this statement shall not be construed as an admission
that any such person or entity is the beneficial owner of any such securities.

(b) Percent of class:

The following percentages are based
on a denominator which is the sum of: (i) 71,171,551 shares of Common Stock outstanding as of July 20, 2017, as disclosed in the
Issuer’s Quarterly Report filed on Form 10-Q with the Securities and Exchange Commission on August 4, 2017, (ii) the 15,918,751
Shares of Common Stock issued by the Issuer pursuant to the Private Placement and (iii) certain of the 2,439,932 shares of Common
Stock underlying certain Warrants, as applicable.

11

Follow Arqule Inc (NASDAQ:ARQL)

Page 12 of 14 – SEC Filing

As of October
16, 2017 (i) BVF beneficially owned approximately 10.0% of the outstanding shares of Common Stock, including shares of Common Stock
issuable upon the exercise of certain Warrants, (ii) BVF2 beneficially owned approximately 5.8% of the outstanding shares of Common
Stock, including shares of Common Stock issuable upon the exercise of certain Warrants, (iii) Trading Fund OS beneficially owned
approximately 1.6% of the outstanding shares of Common Stock, (iv) Partners OS may be deemed to beneficially own approximately
1.6% of the outstanding shares of Common Stock, and (v) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially
own approximately 19.9% of the outstanding shares of Common Stock (approximately 2.5% of which is held in the Partners Managed
Accounts).

(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of

See Cover Pages Items 5-9.

Item 5. Ownership of Five Percent or Less of a Class.

Not Applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Partners, BVF Inc. and Mr. Lampert
share voting and dispositive power over the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners
Managed Accounts.

Item 7. Identification and Classification of the Subsidiary That Acquired the Security Being Reported on
by the Parent Holding Company or Control Person.

Not Applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 99.1 to Amendment No. 3
to the Schedule 13G filed with the Securities and Exchange Commission on February 16, 2016.

Item 9. Notice of Dissolution of Group.

Not Applicable.

12

Follow Arqule Inc (NASDAQ:ARQL)

Page 13 of 14 – SEC Filing

Item 10. Certifications.

By signing below each of
the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and
are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were
not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

13

Follow Arqule Inc (NASDAQ:ARQL)

Page 14 of 14 – SEC Filing

SIGNATURE

After reasonable inquiry
and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement
is true, complete and correct.

Dated: October 16, 2017

BIOTECHNOLOGY VALUE FUND, L.P. BVF INC.
 
By: BVF Partners L.P., its general partner By:

/s/ Mark N. Lampert
By: BVF Inc., its general partner Mark N. Lampert
  President
By:

/s/ Mark N. Lampert
Mark N. Lampert
President

/s/ Mark N. Lampert
  MARK N. LAMPERT
 
BIOTECHNOLOGY VALUE FUND II, L.P.
 
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
 
By:

/s/ Mark N. Lampert
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
 
By:

/s/ Mark N. Lampert
Mark N. Lampert
President
BVF PARTNERS OS LTD.
By: BVF Partners L.P., its sole member
By: BVF Inc., its general partner
 
By:

/s/ Mark N. Lampert
Mark N. Lampert
President
14

Follow Arqule Inc (NASDAQ:ARQL)

Related Insider Monkey Articles
13G Filing: Bison Capital Partners V, L.P. and General Finance Corp (GFN)13G Filing: Saba Capital and Templeton Emerging Markets Income Fund (TEI)
13G Filing: Intracoastal Capital, LLC and Aethlon Medical Inc (AEMD)13G Filing: Viking Global and Deciphera Pharmaceuticals LLC (DCPH)
13G Filing: VR Global Partners, L.P. and Adeptus Health Inc. (ADPT)13G Filing: Palo Alto Investors and Alimera Sciences Inc (ALIM)